{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:08:28Z","timestamp":1793725708375,"version":"4.6.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40120-026-00989-x","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:56:33Z","timestamp":1784163393000},"page":"2449-2465","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative Evaluation of Rituximab Versus Approved Therapies in Aquaporin-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder: A Systematic Review and Network Meta-analysis"],"prefix":"10.1007","volume":"15","author":[{"given":"Mahdi","family":"Barzegar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Samadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Audoin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Berthele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayse","family":"Altintas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Willekens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sini","family":"Laakso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shima","family":"Jahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa","family":"Zappe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Lefter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aksel","family":"Siva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Afshari-Safavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f6ren","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrijs","family":"Wokke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Cortese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Illes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saif","family":"Huda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rommer","family":"Paulus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Collongues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Ringelstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Cobo-Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Hacohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Arrambide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Palace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Mariotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Marignier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Geraldes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedemann","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8551-0947","authenticated-orcid":false,"given":"Nasrin","family":"Asgari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"MEDEN study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"issue":"4","key":"989_CR1","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1084\/jem.20050304","volume":"202","author":"VA Lennon","year":"2005","unstructured":"Lennon VA, Kryzer TJ, Pittock SJ, Verkman A, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202(4):473\u20137.","journal-title":"J Exp Med"},{"issue":"7","key":"989_CR2","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1177\/1352458515620934","volume":"22","author":"BA Cree","year":"2016","unstructured":"Cree BA, Bennett JL, Sheehan M, et al. Placebo-controlled study in neuromyelitis optica\u2014ethical and design considerations. Mult Scler J. 2016;22(7):862\u201372.","journal-title":"Mult Scler J"},{"issue":"9451","key":"989_CR3","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","volume":"364","author":"VA Lennon","year":"2004","unstructured":"Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106\u201312.","journal-title":"Lancet"},{"issue":"1","key":"989_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","volume":"6","author":"S Jarius","year":"2020","unstructured":"Jarius S, Paul F, Weinshenker BG, Levy M, Kim HJ, Wildemann B. Neuromyelitis optica. Nat Rev Dis Primers. 2020;6(1):85.","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"989_CR5","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/s41582-024-01014-1","volume":"20","author":"A Uzawa","year":"2024","unstructured":"Uzawa A, Oertel FC, Mori M, Paul F, Kuwabara S. NMOSD and MOGAD: an evolving disease spectrum. Nat Rev Neurol. 2024;20(10):602\u201319.","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"989_CR6","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/cei.12271","volume":"176","author":"S Jarius","year":"2014","unstructured":"Jarius S, Wildemann B, Paul F. Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol. 2014;176(2):149\u201364.","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"989_CR7","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1212\/01.WNL.0000049912.02954.2C","volume":"60","author":"DM Wingerchuk","year":"2003","unstructured":"Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology. 2003;60(5):848\u201353.","journal-title":"Neurology"},{"issue":"1","key":"989_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1742-2094-9-14","volume":"9","author":"S Jarius","year":"2012","unstructured":"Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation. 2012;9(1):14.","journal-title":"J Neuroinflammation"},{"issue":"1","key":"989_CR9","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S1474-4422(20)30392-6","volume":"20","author":"M Levy","year":"2021","unstructured":"Levy M, Fujihara K, Palace J. New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol. 2021;20(1):60\u20137.","journal-title":"Lancet Neurol"},{"issue":"1","key":"989_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","volume":"261","author":"C Trebst","year":"2014","unstructured":"Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 2014;261(1):1\u201316.","journal-title":"J Neurol"},{"key":"989_CR11","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","volume":"264","author":"Z Nikoo","year":"2017","unstructured":"Nikoo Z, Badihian S, Shaygannejad V, Asgari N, Ashtari F. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol. 2017;264:2003\u20139.","journal-title":"J Neurol"},{"issue":"4","key":"989_CR12","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","volume":"19","author":"M Tahara","year":"2020","unstructured":"Tahara M, Oeda T, Okada K, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020;19(4):298\u2013306.","journal-title":"Lancet Neurol"},{"issue":"1","key":"989_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","volume":"271","author":"T K\u00fcmpfel","year":"2024","unstructured":"K\u00fcmpfel T, Giglhuber K, Aktas O, et al. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD)\u2014revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. J Neurol. 2024;271(1):141\u201376.","journal-title":"J Neurol"},{"issue":"2","key":"989_CR14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","volume":"159","author":"A Cipriani","year":"2013","unstructured":"Cipriani A, Higgins JP, Geddes JR, Salanti G. Conceptual and technical challenges in network meta-analysis. Ann Intern Med. 2013;159(2):130\u20137.","journal-title":"Ann Intern Med"},{"issue":"1","key":"989_CR15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40120-021-00295-8","volume":"11","author":"DM Wingerchuk","year":"2022","unstructured":"Wingerchuk DM, Zhang I, Kielhorn A, et al. Network meta-analysis of food and drug administration-approved treatment options for adults with aquaporin-4 immunoglobulin\u00a0G-positive neuromyelitis optica spectrum disorder. Neurol Ther. 2022;11(1):123\u201335.","journal-title":"Neurol Ther"},{"issue":"3","key":"989_CR16","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s40120-024-00597-7","volume":"13","author":"SL Clardy","year":"2024","unstructured":"Clardy SL, Pittock SJ, Aktas O, et al. Network meta-analysis of ravulizumab and alternative interventions for the treatment of neuromyelitis optica spectrum disorder. Neurol Ther. 2024;13(3):535\u201349.","journal-title":"Neurol Ther"},{"key":"989_CR17","doi-asserted-by":"publisher","first-page":"1166490","DOI":"10.3389\/fneur.2023.1166490","volume":"14","author":"S Aungsumart","year":"2023","unstructured":"Aungsumart S, Youngkong S, Dejthevaporn C, et al. Efficacy and safety of monoclonal antibody therapy in patients with neuromyelitis optica spectrum disorder: a systematic review and network meta-analysis. Front Neurol. 2023;14:1166490.","journal-title":"Front Neurol"},{"issue":"6","key":"989_CR18","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1007\/s00415-023-11641-1","volume":"270","author":"Z Yin","year":"2023","unstructured":"Yin Z, Qiu Y, Duan A, et al. Different monoclonal antibodies and immunosuppressants administration in patients with neuromyelitis optica spectrum disorder: a Bayesian network meta-analysis. J Neurol. 2023;270(6):2950\u201363.","journal-title":"J Neurol"},{"issue":"8","key":"989_CR19","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1177\/13524585231172145","volume":"29","author":"BG Weinshenker","year":"2023","unstructured":"Weinshenker BG, Wingerchuk DM, Green AJ, et al. Attack adjudication in neuromyelitis optica spectrum disorder: substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum. Mult Scler J. 2023;29(8):945\u201355.","journal-title":"Mult Scler J"},{"key":"989_CR20","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. bmj. 2021;372:n71.","DOI":"10.1136\/bmj.n71"},{"issue":"3","key":"989_CR21","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/14728214.2020.1803828","volume":"25","author":"A Duchow","year":"2020","unstructured":"Duchow A, Chien C, Paul F, Bellmann-Strobl J. Emerging drugs for the treatment of neuromyelitis optica. Expert Opin Emerg Drugs. 2020;25(3):285\u201397.","journal-title":"Expert Opin Emerg Drugs"},{"issue":"3","key":"989_CR22","doi-asserted-by":"publisher","first-page":"494","DOI":"10.11124\/JBIES-22-00430","volume":"21","author":"TH Barker","year":"2023","unstructured":"Barker TH, Stone JC, Sears K, et al. The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials. JBI Evid Synth. 2023;21(3):494\u2013506.","journal-title":"JBI Evid Synth"},{"issue":"24","key":"989_CR23","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","volume":"17","author":"MK Parmar","year":"1998","unstructured":"Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815\u201334.","journal-title":"Stat Med"},{"issue":"5","key":"989_CR24","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/sim.4780100510","volume":"10","author":"G Berry","year":"1991","unstructured":"Berry G, Kitchin R, Mock P. A comparison of two simple hazard ratio estimators based on the logrank test. Stat Med. 1991;10(5):749\u201355.","journal-title":"Stat Med"},{"issue":"22","key":"989_CR25","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","volume":"381","author":"T Yamamura","year":"2019","unstructured":"Yamamura T, Kleiter I, Fujihara K, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(22):2114\u201324.","journal-title":"N Engl J Med"},{"issue":"5","key":"989_CR26","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","volume":"19","author":"A Traboulsee","year":"2020","unstructured":"Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase\u00a03 trial. Lancet Neurol. 2020;19(5):402\u201312.","journal-title":"Lancet Neurol"},{"issue":"7","key":"989_CR27","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","volume":"381","author":"SJ Pittock","year":"2019","unstructured":"Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(7):614\u201325.","journal-title":"N Engl J Med"},{"issue":"10206","key":"989_CR28","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","volume":"394","author":"BA Cree","year":"2019","unstructured":"Cree BA, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase\u00a02\/3 trial. Lancet. 2019;394(10206):1352\u201363.","journal-title":"Lancet"},{"issue":"5","key":"989_CR29","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","volume":"19","author":"C Zhang","year":"2020","unstructured":"Zhang C, Zhang M, Qiu W, et al. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase\u00a02 trial. Lancet Neurol. 2020;19(5):391\u2013401.","journal-title":"Lancet Neurol"},{"issue":"6","key":"989_CR30","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/ana.26626","volume":"93","author":"SJ Pittock","year":"2023","unstructured":"Pittock SJ, Barnett M, Bennett JL, et al. Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. Ann Neurol. 2023;93(6):1053\u201368.","journal-title":"Ann Neurol"},{"issue":"6","key":"989_CR31","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1093\/brain\/aws109","volume":"135","author":"J Kitley","year":"2012","unstructured":"Kitley J, Leite MI, Nakashima I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain. 2012;135(6):1834\u201349.","journal-title":"Brain"},{"issue":"2","key":"989_CR32","first-page":"205521732110068","volume":"7","author":"S Asseyer","year":"2021","unstructured":"Asseyer S, Masuda H, Mori M, et al. AQP4-IgG autoimmunity in Japan and Germany: differences in clinical profiles and prognosis in seropositive neuromyelitis optica spectrum disorders. Mult Scler J Exp Transl Clin. 2021;7(2):20552173211006864.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"989_CR33","doi-asserted-by":"publisher","first-page":"111537","DOI":"10.1016\/j.jclinepi.2024.111537","volume":"176","author":"ID Florez","year":"2024","unstructured":"Florez ID, Juan E, Veroniki A-A. Network meta-analysis: a powerful tool for clinicians, decision-makers, and methodologists. J Clin Epidemiol. 2024;176:111537.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"989_CR34","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1037","volume":"3","author":"G Salanti","year":"2012","unstructured":"Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods. 2012;3(2):80\u201397.","journal-title":"Res Synth Methods"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00989-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00989-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00989-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:02:35Z","timestamp":1790380955000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00989-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["989"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00989-x","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"5 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Sini Laakso has received lecture fees from Alexion, Argenx, Janssen, Lundbeck, Merck, Novartis, Sanofi, and Teva; congress and travel expenses from Merck, Novartis, and UCB Pharma; and advisory fees from Argenx, Johnson & Johnson, Novartis, Sanofi, and UCB Pharma. Barbara Willekens has received lecture fees from Alexion, Argenx, Janssen, Lundbeck, Merck, Novartis, Sanofi, and Teva; congress and travel support from Merck, Novartis, and UCB Pharma; and advisory fees from Argenx, Johnson & Johnson, Novartis, Sanofi, and UCB Pharma. Silvia Messina has received speaker honoraria from UCB, Amgen, Novartis, TSF, Dynamics, Biogen, Roche, Sanofi, and Alexion, and has received research grants from the Italian Ministry of Health, Lundbeck, Euroimmun, TSF, GJF, and FISM. Mahdi Barzegar is an Advisory Board member of\n                      Neurology and Therapy\n                      . Sara Samadzadeh, Bertrand Audoin, Achim Berthele, Ayse Altintas, Shima Jahani, Viktoria Papp, Clarissa Zappe, Antonia Lefter, Aksel Siva, Alireza Afshari-Safavi, S\u00f6ren M\u00f6ller, Beatrijs Wokke, Rosa Cortese, Zsolt Illes, Saif Huda, Rommer Paulus, Nicolas Collongues, Marius Ringelstein, \u00c1lvaro Cobo-Calvo, Yael Hacohen, Georgina Arrambide, Jacqueline Palace, Sara Mariotto, Romain Marignier, Ruth Geraldes, Friedemann Paul, and Nasrin Asgari have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is a systematic review and network meta-analysis of previously published data. As no primary data collection from human participants was conducted, ethical approval was not required.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}